Biochem/physiol Actions
PRKG1 is a homodimer, with each monomer containing a regulatory cGMP-binding domain and a catalytic domain. By Northern blot analysis PRKG1 was shown to be expressed at highest levels in bladder, uterus, adrenal gland, and fallopian tube. PRKG1 plays an important stimulatory role in platelet activation. Expression of recombinant PRKG1 in a reconstituted cell model enhanced von Willebrand factor-induced activation of the platelet integrin alpha-IIb/beta-3. Prkg1 knockout mice showed impaired platelet responses to VWF or low doses of thrombin and prolonged bleeding time. Human platelet aggregation induced by VWF or low-dose thrombin was inhibited by PRKG1 inhibitors but enhanced by cGMP.
Physical form
Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.
Legal Information
PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany
| recombinant | expressed in baculovirus infected Sf9 cells |
| Quality Segment | 200 |
| product line | PRECISIO® Kinase |
| assay | ≥70% (SDS-PAGE) |
| form | buffered aqueous glycerol solution |
| specific activity | 663-897 nmol/min·mg |
| mol wt | ~100 kDa |
| UniProt accession no. | Q13976 |
| shipped in | dry ice |
| storage temp. | −70°C |
| Gene Information | human ... PRKG1(5592) |
